Know Cancer

or
forgot password

Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients


Phase 1
2 Years
20 Years
Not Enrolling
Both
Abdominal Neoplasms, Pelvic Neoplasms

Thank you

Trial Information

Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients


Inclusion Criteria:



- Age: 2-20 years old

- Subject has a known or suspected solid soft tissue tumor in the abdomen or pelvis.

- Subject is scheduled for other imaging or is already scheduled for an ultrasound or
has already had adequate imaging performed at an outside institution.

- Subject is able to lie still for the exam without sedation.

Exclusion Criteria:

- Known or suspected hypersensitivity to albumin, blood or blood products.

- History of open heart surgery, cyanotic congenital heart disease or an axygen
saturation of less than 96% as determined by pulse oximetry.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To learn the best dose of Optison™ ultrasound contrast agent that can be safely given to children with abdominal or pelvic tumors.

Outcome Time Frame:

Unknown-study temporarily closed.

Safety Issue:

Yes

Principal Investigator

Mary E. McCarville, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Jude Children's Research Hospital

Authority:

United States: Food and Drug Administration

Study ID:

OPTUS

NCT ID:

NCT00186953

Start Date:

June 2002

Completion Date:

August 2004

Related Keywords:

  • Abdominal Neoplasms
  • Pelvic Neoplasms
  • Ultrasound
  • Abdominal tumors
  • Pelvic tumors
  • Abdominal Neoplasms
  • Neoplasms
  • Pelvic Neoplasms

Name

Location

St. Jude Children's Research HospitalMemphis, Tennessee  38105-2794